IL-10's Dual Role in Cancer Immunity: Review Maps Context-Dependent Framework as Phase III Failure Tempers Enthusiasm
核心洞察
A new review in Frontiers in Immunology synthesizes evidence that IL-10 can enhance CD8+ T-cell and NK-cell antitumor immunity while also reinforcing immunosuppressive myeloid programs in other tumor contexts.
The authors propose a combinatorial signaling model in which STAT1, STAT3 (搜索), STAT5, mTORC1 (搜索), NF-kB/AP-1, receptor density, and chromatin state determine whether IL-10 signaling is beneficial or harmful.
Pegilodecakin, the only IL-10-based agent to complete a randomized phase III oncology trial, failed to improve overall survival in gemcitabine-refractory pancreatic cancer (搜索) despite on-target immune activation.
Interleukin-10, long defined as a prototypical anti-inflammatory cytokine that restrains myeloid activation and limits inflammatory cytokine production, can also enhance cytotoxic antitumor immunity under defined conditions — but the same pathway can reinforce immunosuppressive programs in other tumor contexts, according to a review published in Frontiers in Immunology. The authors argue that IL-10 should be viewed neither as simply anti-inflammatory nor as an antitumor enhancer, but as a pleiotropic immunoregulatory cytokine whose effects depend on the cellular and tissue context in which signaling occurs.
The review synthesizes mechanistic and translational evidence with what it describes as conflicting and cautionary data, including the failure of pegilodecakin — the only IL-10-based agent to complete a randomized phase III oncology trial — to improve survival in gemcitabine-refractory pancreatic cancer (搜索).
A Shared Signaling Hub With Divergent Outputs
IL-10 signals through a heterohexameric receptor complex comprising one IL-10 homodimer, two high-affinity IL-10Rα chains, and two accessory IL-10Rβ chains. Ligand binding juxtaposes receptor-associated JAK1 and TYK2, enabling their mutual activation and initiating JAK–STAT signaling. STAT3 (搜索) is the dominant effector, although STAT1 can also be engaged in a context-dependent manner.
In myeloid cells, STAT3 (搜索) induces an anti-inflammatory transcriptional program including SOCS3, BCL3, TNFAIP3/A20, and IL1RN that dampens NF-κB and MAPK signaling and selectively suppresses production of TNF-α, IL-1β, IL-6, IL-12, and IL-23. Genetic deletion or functional disruption of STAT3 in macrophages and neutrophils abrogates IL-10 responsiveness.
The authors contend that this canonical pathway does not fully explain the diversity of biological responses observed across cell types. They propose that IL-10R (搜索) output is determined combinatorially by the receptor chains and kinases engaged, parallel signaling pathways, receptor abundance and signaling duration, and the transcriptional and epigenetic state of responding cells. Supporting evidence includes STAT1 activation alongside STAT3 (搜索) in myeloid cells; engineered surrogate agonists that rewire IL-10R-chain pairing to predominantly activate STAT5; an IL-10R–STAT3–mTORC1 (搜索) axis required for NK-cell metabolic reprogramming; and genome-wide mapping showing STAT3 binds predominantly within pre-existing, nucleosome-depleted chromatin rather than opening new regulatory regions.
Direct Effects on Cytotoxic Lymphocytes
Following activation, CD8+ T cells upregulate IL-10R (搜索), increasing their responsiveness to IL-10. In multiple tumor models, delivery of IL-10 through minicircle DNA, recombinant protein, or PEGylated formulations preferentially activated pre-existing tumor-resident CD8+ T cells rather than broadly stimulating systemic T-cell populations, promoting local proliferation and marked induction of IFN-γ, granzyme B, and perforin. Blocking T-cell trafficking did not abrogate IL-10-induced tumor rejection, and IL-10Rβ-deficient CD8+ T cells failed to expand or acquire the enhanced effector phenotype — evidence the authors describe as establishing that direct IL-10R signaling in endogenous CD8+ tumor-infiltrating lymphocytes is necessary and, under the experimental conditions tested, sufficient for IL-10-driven tumor control.
IL-10 also acts directly on NK cells, increasing IFN-γ production, elevating granzyme B, and inducing IFN-γ-responsive chemokines such as CXCL10/IP-10. IL-10 can augment NK-cell killing in a dose-dependent manner, including against tumor targets otherwise relatively resistant to NK-cell lysis.
Beyond effector programming, the review describes evidence that IL-10 supports cytotoxic lymphocyte survival and persistence, restrains terminal exhaustion, and reprograms cellular metabolism. In a defined preclinical model, a half-life-extended IL-10–Fc fusion protein preferentially engaged terminally exhausted PD-1hi TIM-3+ CD8+ TILs, which express high levels of IL-10R (搜索), and remodeled their mitochondrial metabolism — increasing mitochondrial mass, membrane potential, spare respiratory capacity, and oxidative phosphorylation via upregulation of the mitochondrial pyruvate carrier complex. Pharmacological or genetic disruption of mitochondrial pyruvate transport abrogated these effects. The authors note that several of these mechanisms remain supported primarily by limited preclinical models and correlative human data.
A Decision Framework for Agonism Versus Blockade
The review proposes a context-dependent framework, derived from mechanistic studies, heterogeneous preclinical models, and correlative patient data but not yet prospectively validated, for anticipating whether IL-10 agonism or IL-10R (搜索) blockade is more likely to be beneficial. Features favoring IL-10 agonism include T-cell/NK-cell-inflamed tumors, higher IL-10R expression on CD8+ TILs than on tumor-associated macrophages or dendritic cells, low-to-moderate baseline IL-10, low Treg/TAM abundance, higher tumor antigenicity, intact IFN-γ pathway responsiveness, and a stem-like PD-1int TCF-1+ TIL pool. Features favoring IL-10R blockade include myeloid-dominant tumors, higher IL-10R expression on TAMs/DCs, already elevated IL-10, high Treg/TAM abundance, and predominantly terminally exhausted or metabolically collapsed TILs.
Multiple myeloma (搜索) is cited as a representative setting for blockade: IL-10R (搜索) signaling sustains TAM-mediated resistance to proteasome inhibitors, whereas IL-10R blockade reprogrammed TAMs and restored drug sensitivity. For intermediate contexts, the authors suggest tumor-targeted or cell-selective IL-10 formats may offer a rational alternative to systemic agonism or systemic blockade.
Engineering Platforms and the Phase III Cautionary Tale
The review catalogues a range of engineering strategies. PEGylation extends IL-10's short circulating half-life — less than 5 hours in humans — and pegilodecakin induced pharmacodynamic changes consistent with systemic immune activation in early-phase trials, including expansion of activated CD8+ T-cell populations. However, the randomized phase III SEQUOIA trial of pegilodecakin plus FOLFOX (搜索) in gemcitabine-refractory pancreatic cancer (搜索) did not improve overall survival, progression-free survival, or objective response rate compared with FOLFOX alone. Exploratory analyses nevertheless showed increases in IFN-γ, granzyme B, and IL-18, consistent with on-target immune activation — a dissociation the authors call a major cautionary finding for the field.
In the SEQUOIA trial, grade ≥3 adverse events occurring at least 5% more frequently with pegilodecakin plus FOLFOX (搜索) than with FOLFOX alone included thrombocytopenia (25.2% vs. 3.6%), anemia (16.2% vs. 4.0%), neutropenia (29.5% vs. 22.7%), and fatigue (17.6% vs. 10.8%). In a phase I dose-escalation study of pegilodecakin monotherapy in advanced solid tumors (AM0010), dose-limiting toxicities included thrombocytopenia and anemia, consistent with the known effects of IL-10 on hematopoietic progenitors.
Other formats in development include IL-10–Fc fusions that extend half-life through FcRn-mediated recycling; covalently stabilized IL-10 dimers engineered with flexible peptide linkers; myeloid-targeted fusion proteins such as BF10 (搜索), an anti-CSF1R (搜索)–IL-10 molecule that reduced suppressive TAM and Treg populations and improved responsiveness to PD-1 blockade in preclinical models; and tumor-targeted immunocytokines such as an EGFR (搜索)-targeted IL-2/IL-10 construct that reduced cytokine storm-like inflammatory signatures while increasing intratumoral CD8+ T-cell activation in murine models.
A super-agonist approach increased IL-10 affinity for IL-10Rβ using yeast surface display and structure-guided mutagenesis, inducing IL-10-responsive gene expression at substantially lower concentrations and, in combination with IL-2, enhancing the cytolytic activity of tumor-specific CAR-T cells relative to wild-type IL-10 supplementation. Bispecific VHH-based surrogate agonists that force receptor-chain co-engagement — IL-2Rβ×IL-10Rβ and IL-10Rα×IL-2Rγ — demonstrate that signaling output depends on which receptor-associated JAK kinases are physically juxtaposed, with the former predominantly activating STAT5 rather than the native STAT3 (搜索)-dominant output.
IL-10-Armored Cell Therapy Reaches the Clinic
Adoptive immune cells engineered to secrete IL-10 locally have begun clinical evaluation. META10-19, an IL-10-secreting anti-CD19 (搜索) CAR-T product, produced high rates of measurable residual disease-negative complete remission in a first-in-human phase I study of relapsed or refractory B-cell acute lymphoblastic leukemia (搜索) following a single low-dose infusion. Most cytokine release syndrome events were grade 1 or 2, and no immune effector cell-associated neurotoxicity syndrome was reported. The product underwent substantial in vivo expansion that correlated with serum IL-10 levels.
The authors caution that the study was small, single-arm, and conducted in one hematologic malignancy, so it cannot establish that IL-10 secretion caused the observed responses. Unresolved safety questions include whether IL-10-armored products suppress adjacent non-target immune populations in vivo, whether enhanced persistence increases selective pressure for antigen-loss escape, and how these therapies behave in solid tumors with more complex myeloid and stromal compartments.
Four Design Principles for Translation
The review concludes with four interrelated principles. First, spatiotemporal control of IL-10 delivery will be critical, with delayed or sustained delivery after immune priming potentially advantageous because it may preferentially engage terminally exhausted PD-1hi TIM-3+ TILs with high IL-10R (搜索) expression. Second, rational combination with complementary immunotherapies — including PD-1/PD-L1 blockade and, in myeloid-suppressive tumors, agents such as anti-CSF1R (搜索) or anti-CD47 therapies — will likely be needed. Third, biomarker-guided patient selection will be essential, with candidate biomarkers including IL-10R abundance on CD8+ TILs versus TAMs/DCs, the balance between stem-like and terminally exhausted TIL subsets, circulating and intratumoral IL-10, IFN-γ, CXCL9, and CXCL10 levels, exhaustion-associated transcriptional markers such as TCF-1 and TOX, and metabolic indicators of mitochondrial fitness. Fourth, safety must be incorporated into therapeutic design and assessed with the same rigor as efficacy from the earliest stages.
The authors emphasize that pharmacodynamic findings should not yet be interpreted as reliable predictors of clinical benefit, citing SEQUOIA as evidence of the limitations of using pharmacodynamic biomarkers as surrogate endpoints before formal validation against clinical outcomes. IL-10-based platforms remain at an early stage of clinical validation across tumor types, with one negative randomized phase III trial and a broader body of early-phase, uncontrolled, and preclinical evidence supporting continued investigation.